Matthew Hammond, Ph.D., 37, has been our Chief Executive Officer and a director since February 2026. Dr. Hammond is a Partner on the Investment Team at RA Capital Management since December 2024 and has been with RA Capital Management since December 2014. He works on both public and private healthcare companies. Dr. Hammond has served as a member of the board of directors of Ambros Therapeutics since September 2025. Dr. Hammond is the former CFO of Research Alliance Corp. I from April 2020 to June 2021, which merged with POINT Biopharma Inc. and previously served on the boards of directors of Jnana Therapeutics (acquired by Otsuka) from August 2021 to September 2024, Forge Biologics (acquired by Ajinomoto) from April 2021 to December 2023, DTx Pharma, Inc. (acquired by Novartis) from February 2021 to July 2023, and Emergence Therapeutics (acquired by Eli Lilly) from February 2022 to August 2023. Dr. Hammond holds a B.S. in Environmental Health Science from University of Georgia and both a Ph.D. in Biomedical Science and an MBA with a concentration in Finance from University of Connecticut. His graduate research investigated innate immune responses after intracerebral hemorrhage. We believe that Dr. Hammond’s experience in the healthcare industry makes him well qualified to serve on our board of directors.

Henry Stusnick, 28, has been our Chief Business Officer and Chief Operating Officer since February 2026. Mr. Stusnick is an Analyst on the Investment Team at RA Capital Management and has been with RA Capital Management since 2022. Mr. Stusnick works on both public and private investments and has served as a director for Kinaset Therapeutics since January 2026, as well as a board observer for Ambros Therapeutics and Sparrow Pharmaceuticals. He previously served as a board observer for Bluejay Therapeutics (acquired by Mirum Pharmaceuticals) and SpyGlass Pharmaceuticals (Nasdaq: SGP). Prior to joining RA Capital Management, Mr. Stusnick worked as an Investment Banker at Leerink Partners, advising biopharma companies on financing and strategic transactions. Mr. Stusnick holds a B.A. in Biology and Economics from Dartmouth College.

Fran Adams, 45, has been our Chief Financial Officer since February 2026. Mr. Adams is currently a Partner at van den Boom and Associates with over 20 years of accounting and finance experience. Mr. Adams serves as the fractional chief financial officer and head of finance and accounting at various private life sciences companies. Prior to joining van den Boom and Associates worked at multiple public companies focusing on financial reporting and technical accounting. Mr. Adams holds a bachelor’s degree in Business Administration with emphasis in accounting from San Diego State University and is an active California CPA.

Michael F. MacLean, 60, is a director nominee and has over 35 years of financial leadership experience in the biotechnology and life sciences industries, with extensive expertise in public company reporting, capital markets transactions, internal controls, and corporate governance. Mr. MacLean most recently served as Chief Financial Officer of Avidity Biosciences, Inc., a publicly traded company, until its acquisition by Novartis, a position he held from May 2020 through April 2026. He joined Avidity prior to its initial public offering and was responsible for its finance and business functions through its initial public offering and subsequent growth as a multinational organization. He also served as a principal negotiator in connection with the company’s acquisition by Novartis and a multi-target cardiology collaboration with Bristol Myers Squibb. Previously, Mr. MacLean served as Chief Financial Officer of Akcea Therapeutics, Inc. (Nasdaq: AKCA, acquired by Ionis Pharmaceuticals) from 2017 to 2020 and as Chief Financial Officer of PureTech Health plc (LSE: PRTC) from 2015 to 2017. Earlier in his career, he held senior finance roles at Biogen Inc. (NYSE: BIIB), including Senior Vice President, Finance and Chief Accounting Officer, and served as an audit partner at a Big Four accounting firm. Mr. MacLean served on the board of directors of Verve Therapeutics, Inc. (Nasdaq: VERV, acquired by Eli Lilly) from 2021 to 2025 and as Chair of its Audit Committee. Mr. MacLean holds a B.S. in accounting from Boston College Carroll School of Management. We believe that Mr. MacLean’s experience in the healthcare industry makes him well qualified to serve on our board of directors.

Timothy J. Miller, Ph.D., 54, is a director nominee. Dr. Miller previously served as the co-founder and Chief Executive Officer of Forge Biologics, a viral gene therapy contract development and manufacturing organization, from inception in January 2020 through its acquisition by Ajinomoto and into September 2024. Prior to Forge Mr. Miller was co-founder and Chief Executive Officer of Abeona Therapeutics (Nasdaq: ABEO), a gene therapy company, from 2013 to 2018 and President and Chief Science Officer from 2018 to 2020. Dr. Miller holds both a B.S. and M.S. in Biology from John Carroll University and a Ph.D. in pharmacology from Case Western University. We believe Mr. Miller’s more than 30 years of experience in scientific research and product development in the healthcare and life sciences industry makes him well qualified to serve on our board of directors.